**Supplementary**

**Key eligibility criteria**

- Patients with unresectable, stage IIIA or IIIB non-squamous NSCLC
- ECOG PS 0 or 1
- Age 20–75 years

**UP Arm (UFT/Cisplatin)**

- UFT 400 mg/m², day 1–14
- CDDP 80 mg/m², day 8
- q3w x 3 cycles
- IFRT 2Gy x 5 days/week, day 1–45, 66Gy

**PP Arm (Pemetrexed/Cisplatin)**

- PEM 500 mg/m², day 1
- CDDP 75 mg/m², day 1
- q3w x 3 cycles
- IFRT 2Gy x 5 days/week, day for LA-NSCLC

**Randomize 1:1**

**Consolidation**

- Consolidation is not allowed.
- Chemotherapy is terminated after 3 cycle.

**Radiotherapy**

- Involved-field radiotherapy (IFRT) was administered from day 1.
- Total dose was 66Gy in 33 fractions.

**Stratified factor**

- Age 59+/60–64/65–69/70–75
- Gender Male/Female
- Stage IIIA/IIIB (TNM 7th edition)
- EGFR mt status positive/wild/unknown

**Primary endpoint**

- 2-year overall survival

**Secondary endpoint**

- ORR, PFS, OS, Toxicity profile

---

**Figure S1** Treatment schedule of each arm. This figure shows key eligibility criteria and dose of each treatment.